Quantcast
Skip to main content
Environmental Health Perspectives Podcasts - The Researcher's Perspectives
Full
About EHP Publications Past Issues News By Topic Authors Subscribe Press International Inside EHP Email Alerts spacer
Environmental Health Perspectives (EHP) is a monthly journal of peer-reviewed research and news on the impact of the environment on human health. EHP is published by the National Institute of Environmental Health Sciences and its content is free online. Print issues are available by paid subscription.DISCLAIMER
spacer
NIEHS
NIH
DHHS
spacer
Current Issue

EHP Science Education Website




EHP on Twitter

AAAR

Comparative Toxicogenomics Database (CTD)

spacer
Environmental Health Perspectives Volume 111, Number 3, March 2003 Open Access
spacer
Fenitrothion: Toxicokinetics and Toxicologic Evaluation in Human Volunteers

Jean Meaklim,1 Jinming Yang,1 Olaf H. Drummer,2 Sheila Killalea,1 Voula Staikos,2 Soumela Horomidis,2 David Rutherford,3 Lisa L. Ioannides-Demos,1 Stephen Lim,1 Allan J. McLean,4 and John J. McNeil1

1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; 2Victorian Institute of Forensic Medicine and the Department of Forensic Medicine, Monash University, Melbourne, Australia; 3Pathology Department, Alfred Hospital, Melbourne, Australia; 4Clinical Pharmacology Department, Alfred Hospital, Melbourne, Australia

Abstract

An unblinded crossover study of fenitrothion 0.18 mg/kg/day [36 times the acceptable daily intake (ADI) ] and 0.36 mg/kg/day (72 times symbol ADI) administered as two daily divided doses for 4 days in 12 human volunteers was designed and undertaken after results from a pilot study. On days 1 and 4, blood and urine samples were collected for analysis of fenitrothion and its major metabolites, as well as plasma and red blood cell cholinesterase activities, and biochemistry and hematology examination. Pharmacokinetic parameters could only be determined at the higher dosage, as there were insufficient measurable fenitrothion blood levels at the lower dosage and the fenitrooxone metabolite could not be measured. There was a wide range of interindividual variability in blood levels, with peak levels achieved between 1 and 4 hr and a half-life for fenitrothion of 0.8-4.5 hr. Although based on the half-life, steady-state levels should have been achieved ; the area under the curve (AUC) 0-12 hr to AUC0-(infinity) ratio of 1:3 suggested accumulation of fenitrothion. There was no significant change in plasma or red blood cell cholinesterase activity with repeated dosing at either dosage level of fenitrothion, and there were no significant abnormalities detected on biochemical or hematologic monitoring. Key words: , , , . Environ Health Perspect 111:305-308 (2003) .


The full version of this article is available for free in HTML or PDF formats.
spacer
 
Open Access Resources | Call for Papers | Career Opportunities | Buy EHP Publications | Advertising Information | Subscribe to the EHP News Feeds News Feeds | Inspector General USA.gov

Download Adobe Acrobat Reader to view PDF files located on this site.